SEC Form 4 · accession 0000886163-18-000120
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sunil Patel
Director
Period of report
Aug 16, 2018
Accepted (ET)
Aug 17, 2018 · 7:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 16, 2018 | M | 5,000 | $9.60 | A | 44,806 | D | |
| Common Stock | Aug 16, 2018 | M | 7,335 | $10.12 | A | 52,141 | D | |
| Common Stock | Aug 16, 2018 | M | 7,335 | $12.53 | A | 59,476 | D | |
| Common Stock | Aug 16, 2018 | M | 7,335 | $32.30 | A | 66,811 | D | |
| Common StockF1 | Aug 16, 2018 | S | 42,287 | $240.0456 | D | 24,524 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $9.60 | Aug 16, 2018 | M | 5,000 | D | — | Oct 7, 2020 | Common Stock | 5,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F3 | $10.12 | Aug 16, 2018 | M | 7,335 | D | — | Jun 1, 2021 | Common Stock | 7,335 | 0 | D |
| Non-Qualified Stock Option (right to buy)F4 | $12.53 | Aug 16, 2018 | M | 7,335 | D | — | May 31, 2022 | Common Stock | 7,335 | 0 | D |
| Non-Qualified Stock Option (right to buy)F5 | $32.30 | Aug 16, 2018 | M | 7,335 | D | — | Jun 11, 2023 | Common Stock | 7,335 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.31 to $242.68, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2The option becomes exercisable in 36 successive monthly installments upon completion of each calendar month of service beginning on the grant date.
- F3Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date.
- F4Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date.
- F5Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date.